Table 3 Crude incidence and COX analyses of all relevant endpoints
Clinical outcomes | Subgroups of homocysteine | OSA, n (%) | Non-OSA, n (%) | Unadjusted HR (95% CI) | Adjusted HRa (95% CI) |
|---|---|---|---|---|---|
Major adverse cerebrocardiovascular events | NHcy | 121 (23.2) | 83 (17.8) | 1.41 (1.07–1.87) | 1.36 (1.02–1.83) |
HHcy | 59 (19.8) | 54 (20.2) | 1.01 (0.70–1.46) | 0.92 (0.62–1.36) | |
Hospitalization for UA | NHcy | 87 (16.7) | 64 (13.7) | 1.30 (0.94–1.79) | 1.27 (0.90–1.78) |
HHcy | 41 (13.8) | 34 (12.7) | 1.13 (0.72–1.78) | 1.09 (0.67–1.77) | |
Cardiovascular death | NHcy | 9 (1.7) | 6 (1.3) | 1.39 (0.50–3.91) | 1.31 (0.43–3.95) |
HHcy | 5 (1.7) | 7 (2.6) | 0.65 (0.21–2.05) | 0.34 (0.09–1.26) | |
Recurrent MI | NHcy | 13 (2.5) | 12 (2.6) | 1.01 (0.46–2.22) | 0.86 (0.37–2.03) |
HHcy | 11 (3.7) | 4 (1.5) | 2.51 (0.80–7.91) | 2.26 (0.68–7.52) | |
Stroke | NHcy | 13 (2.5) | 6 (1.3) | 2.03 (0.77–5.35) | 1.92 (0.69–5.35) |
HHcy | 6 (2.0) | 8 (3.0) | 0.70 (0.24–2.03) | 0.75 (0.24–2.34) | |
Ischemia-driven revascularization | NHcy | 50 (9.6) | 37 (7.9) | 1.26 (0.83–1.93) | 1.15 (0.73–1.81) |
HHcy | 23 (7.7) | 19 (7.1) | 1.12 (0.61–2.06) | 1.10 (0.58–2.10) | |
Hospitalization for HF | NHcy | 4 (0.8) | 3 (0.6) | 1.27 (0.28–5.66) | 1.29 (0.25–6.59) |
HHcy | 5 (1.7) | 6 (2.2) | 0.73 (0.22–2.39) | 0.32 (0.08–1.29) | |
All repeated revascularization | NHcy | 72 (13.8) | 51 (10.9) | 1.33 (0.93–1.91) | 1.25 (0.85–1.84) |
HHcy | 31 (10.4) | 31 (11.6) | 0.91 (0.55–1.50) | 0.82 (0.49–1.40) | |
Non-culprit revascularization | NHcy | 48 (9.2) | 28 (6.0) | 1.59 (1.00–2.54) | 1.59 (0.97–2.61) |
HHcy | 20 (6.7) | 19 (7.1) | 0.96 (0.51–1.79) | 0.85 (0.44–1.66) | |
All-cause death | NHcy | 11 (2.1) | 11 (2.4) | 0.93 (0.40–2.15) | 0.89 (0.36–2.17) |
HHcy | 6 (2.0) | 8 (3.0) | 0.68 (0.24–1.96) | 0.52 (0.16–1.71) |